Relationship of In Vitro Synergy and Treatment Outcome with Daptomycin plus Rifampin in Patients with Invasive Methicillin-Resistant Staphylococcus aureus Infections
Authors:
Open Access
- 1 July 2013
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 57 (7) , 3450-3452
Abstract
We report the findings of a study examining the relationship between in vitro daptomycin-rifampin synergy and the therapeutic outcome of 12 patients with complex deep methicillin-resistant Staphylococcus aureus (MRSA) infections treated for prolonged periods with this combination. Checkerboard synergy was found in nine cases and was 100% predictive of therapeutic success; absence of synergy was found in three cases, two of which were therapeutic failures ( P = 0.045). No relationship was observed between synergy and outcome by time-kill assessment. Checkerboard synergy may predict clinical response to daptomycin plus rifampin for complex invasive MRSA infections requiring prolonged treatment.Keywords
This publication has 13 references indexed in Scilit:
- Adjunctive Rifampin Is Crucial to Optimizing Daptomycin Efficacy against Rabbit Prosthetic Joint Infection Due to Methicillin-Resistant Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 2011
- Novel Daptomycin Combinations against Daptomycin-Nonsusceptible Methicillin-Resistant Staphylococcus aureus in an In Vitro Model of Simulated Endocardial VegetationsAntimicrobial Agents and Chemotherapy, 2010
- Efficacy of High Doses of Daptomycin versus Alternative Therapies against Experimental Foreign-Body Infection by Methicillin-Resistant Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 2009
- Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin® Outcomes Registry and Experience (CORE)International Journal of Antimicrobial Agents, 2009
- Evaluation of Daptomycin Pharmacodynamics and Resistance at Various Dosage Regimens against Staphylococcus aureus Isolates with Reduced Susceptibilities to Daptomycin in an In Vitro Pharmacodynamic Model with Simulated Endocardial VegetationsAntimicrobial Agents and Chemotherapy, 2008
- Clinical Experience with Daptomycin for the Treatment of Patients with Documented Gram-Positive Septic ArthritisAnnals of Pharmacotherapy, 2008
- Clinical Experience with Daptomycin for the Treatment of Patients with OsteomyelitisThe American Journal of Medicine, 2007
- Activity of Daptomycin Alone and in Combination with Rifampin and Gentamicin against Staphylococcus aureus Assessed by Time-Kill MethodologyAntimicrobial Agents and Chemotherapy, 2007
- Antimicrobial Activities of Ceragenins against Clinical Isolates of Resistant Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 2007
- Synergy, antagonism, and what the chequerboard puts between themJournal of Antimicrobial Chemotherapy, 2003